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Proopiomelanocortin (POMC) is synthesized predominantly in
pituitary corticotrophs, melanotrophs, and arcuate hypotha-
lamic neurons. Corticotroph-derived ACTHmediates basal and
stress-induced glucocorticoid secretion, but it is uncertain
whetherPOMCpeptidesproduced in thebrainalso regulate the
hypothalamic-pituitary-adrenal axis. To address this question,
we generated neuron-specific POMC-deficient mice by trans-
genic (Tg) replacement of pituitary POMC in a global Pomc/
background.Selective restorationofpituitaryPOMCprevented
the adrenal insufficiency and neonatal mortality characteristic
ofPomc/mice. However, adultPomc/Tg/mice expressing
the pituitary-specific transgene exhibited adrenal cortical hy-
pertrophy, elevated basal plasma corticosterone, elevated basal
but attenuated stress-inducedACTH secretion, and inappropri-
ately elevated CRH expression in the hypothalamic paraven-
tricular nucleus. In addition, Pomc/Tg/, Pomc/Tg/, and
Pomc/mice, which all displayed varying degrees of elevated
CRH, frequently developedmelanotroph adenomas after 1 yr of
age, whereasPomc/mice, withmaximal CRH expression and
glucocorticoid disinhibition, developed corticotroph and mela-
notroph adenomas. These results indicate that neuronal POMC
peptides are necessary to regulate CRH within physiological
limits and that a chronic reduction or absence of
hypothalamic POMC leads to trophic stimulation of pituitary
cells directly or indirectly through elevated CRH levels.
THE HYPOTHALAMIC-PITUITARY-ADRENAL (HPA)axis mediates the core neuroendocrine response to
stress (1). Within the hypothalamus, the paraventricular nu-
cleus (PVH) is the nodal point for integration of environ-
mental and interoceptive triggers of stress. A subpopulation
of parvicellular, hypophyseotropic PVH neurons releases
CRH from terminals in the median eminence whereby CRH
reaches its target pituitary cells via a portal venous plexus.
CRH activates CRH-R1 receptors located on both anterior
lobe corticotrophs and intermediate lobe melanotrophs to
induce proopiomelanocortin (Pomc) gene expression and
hormone secretion (2–4). ACTH, derived from the posttrans-
lational processing of proopiomelanocortin (POMC) in pi-
tuitary corticotrophs, is the principal mediator of basal and
stress-induced glucocorticoid secretion from the adrenal cor-
tex (5). Circulating glucocorticoids provide a negative feed-
back signal to the limbic-HPA axis at multiple levels in the
brain and also directly on corticotrophs, but not mela-
notrophs, due to the differential cell-specific expression of
glucocorticoid receptors (3, 4, 6).
In addition to its expression in the pituitary, the Pomc gene
is highly expressed in a subpopulation of neurons in the
arcuate nucleus of the hypothalamus (ArcN) that extend
axonal projections tomultiple subcortical nuclei (7, 8). POMC
processing in ArcN and in a second smaller population of
POMC neurons located in the nucleus tractus solitarius
yields a family of melanocortin peptides together with the
potent opioid -endorphin (9). POMC peptides function
physiologically within the central nervous system to mod-
ulate appetite, reward, and autonomic outflow (10–13). Neu-
ronal targets implicated in the anorectic and catabolic effects
of melanocortins include PVH CRH neurons, which are
densely innervated by ArcN POMC terminals (14). A large
percentage of these neurons express melanocortin-4 recep-
tors and respond directly to melanocortin stimulation ac-
companied by increased plasma ACTH, corticosterone, and
decreased food intake (14–17). Opioid peptides including
-endorphin can directlymodulate the function of CRH neu-
rons in the PVH with predominantly inhibitory actions by 
opioid receptor activation and facilitatory actions by  opioid
receptor activation and thereby alter HPA activity (18, 19).
Furthermore, published data conflict with each other con-
cerning whether glucocorticoids have long-loop feedback
effects on the activity of POMC neurons in ArcN and ex-
pression of the Pomc gene analogous to their clearly estab-
lished inhibitory control of pituitary corticotrophs (20, 21).
There is growing evidence for complex reciprocal inter-
actions between nutritional state and HPA axis activity and
among the humoral and neural factors that regulate both
homeostatic systems (22, 23). POMC expression, processing,
and peptide signaling may have coevolved in pituitary cells
and the ontogenetically related medial-basal hypothalamic
neurons (24) to coordinate energy balance and stress respon-
* J.L.S. and V.T. contributed equally to this work.
Abbreviations: ArcN, Arcuate nucleus; EGFP, enhanced green fluo-
rescent protein; HPA, hypothalamic-pituitary-adrenal; POMC, proopio-
melanocortin; PRL, prolactin; PVH, paraventricular nucleus
hypothalamus.
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siveness. A total absence of POMC peptides secondary to
null Pomc gene mutations produces a syndrome of adrenal
insufficiency and early-onset obesity in both humans and
mice (25–27). However, because of the dual nature of POMC
expression in pituitary and brain, it has not been possible to
fully distinguish the contribution of POMC peptides from
each site to the varied components of the syndromeoccurring
in Pomc/ mice.
Therefore, to differentiate among the unique functions and
potential redundancies of POMC produced in the pituitary
and brain, we have restored POMC expression specifically to
the pituitary of Pomc/ mice using a compound transgenic
strategy. Here, we characterize the function of the HPA axis
and report the unanticipated consequences of sustainedHPA
overactivity and pituitary adenoma induction secondary to
central CRH drive in neuronal-specific POMC-deficient
mice.
Materials and Methods
Care and use of animals
All mice for these studies were maintained under controlled tem-
perature and photoperiod (14 h light, 10 h dark; lights on at 0500 h) with
food and water provided ad libitum. All experimental procedures were
approved by the Oregon Health & Science University Institutional An-
imal Care andUseCommittee and followed established guidelines of the
Public Health Service.
Generation and breeding of mice
pHalEx2* transgenicmiceweregeneratedbymicroinjectionof a genomic
Tg construct that selectively expresses POMC in pituitary cells, but not
neurons, with normal hormonal regulation and posttranslational process-
ing (28–30). These transgenic mice were crossbred to the Pomc/ strain on
a mixed hybrid B6;D2;129X1;129S6 genetic background as described fully
in a previous report (28). The resulting compoundmutant mice segregated
into six possible distinct genotypes: Pomc/, Pomc/, or Pomc/ at the
endogenous Pomc locus in combination with either the hemizygous trans-
gene (Tg/) or wild-type chromosomal integration site (/). For one
experiment, mice were further bred to homozygosity for the Tg allele to
produce a cohort consisting of Pomc/Tg/Tg and Pomc/Tg/Tg geno-
types. Additionally, small numbers of a second compound mutant strain
were produced by crossing Pomc/ breeders to an existing inbred B6
transgenic strain that expresses enhanced green fluorescent protein [en-
hanced green fluorescent protein (EGFP)] (Clontech Laboratories, Inc.,
Mountain View, CA) under the control of pituitary and neuronal Pomc
promoter/enhancer elements (31). A third strain of mutant mice, official
designation B6;129S2-Pomc1tm1Low/J (Induced Mutant Resource, The Jack-
son Laboratories), that expresses a truncated POMCprohormone resulting
in a phenotype of selective -endorphin deficiency was produced in our
laboratory (32) and maintained on a congenic B6 genetic background as
described previously (12).
Genotyping
Genotyping of compound Pomc mutant mice was performed as de-
scribed in detail previously (28). An additional PCR detected the Pomc-
EGFP transgene 220 bp product using primer pair 5-TATATCATGGC-
CGACAAGCA-3 and 5-GAACTCCAGCAGGACCATGT-3.
Blood and tissue collection
Mice were singly housed for at least 2 d before blood sampling to
obtain basal, nonstressed hormone levels. Cages were transported in-
dividually to an adjacent roombetween 0700 and 1000 and themicewere
decapitated without anesthesia within 30 sec of cage handling. Trunk
blood was collected into tubes containing EDTA and plasma was im-
mediately separated by centrifugation and frozen. Brains were rapidly
removed, frozen in isopentane, and stored at80 C for later sectioning.
Pituitaries were weighed and stored in buffered 10% formalin or sub-
mersed in a cryomold containing optimal cutting temperature com-
pound and frozen on dry ice. Adrenal glands were dissected free of
surrounding fat, weighed as a pair, and stored in 10% formalin. For acute
stress studies, mice were individually constrained for 20 min inside
cylindrical tubes and then immediately decapitated for trunk blood.
Additionalmicewere anesthetizedwith 2%Avertin, perfused via the left
ventricle with 4% buffered paraformaldehyde, and their brains removed
and postfixed for 16 h.
Histology and immunohistochemistry
Histology was performed on 5-m paraffin sections of adrenal or
pituitary glands stained with hematoxylin and eosin or by the Gordon-
Sweet silver method for reticulin fibers. Pituitary hormone immuno-
histochemistry was performed on either 20-m frozen sections or 5-m
paraffin sections. Antigen retrieval was performed on the latter sections
after deparaffinization and rehydration by treatment of slides with boil-
ing 10 mm trisodium citrate buffer, pH 6.0, for 30 min. After three rinses
in 10 mm 140 mm NaCl, 20 mm K2HPO4, pH 7.4 (KPBS), pituitary
sections were incubated with 2% normal goat serum and 0.3% Triton
X-100 in KPBS containing one of the following primary antisera (A.
Parlow, National Hormone and Peptide Program) at the indicated di-
lutions: antihuman GH (1:2000), antirat prolactin (PRL) (1:25), antirat
FSH (1:6000), antirat TSH (1:500), and antirat ACTH (1:5000) at 4 C
overnight. Sections were then rinsed three times in KPBS and sequen-
tially incubated with 20 g/ml biotinylated goat-antirabbit IgG (Vector
Laboratories, Burlingame, CA) for 2 h at 25 C followed by incubation
with an avidin-biotin horseradish peroxidase complex (Vectastain Elite
ABC Kit; Vector Laboratories) for 1 h at 25 C. Reaction product was
revealed with 1 mg/ml diaminobenzidine containing 0.03%H2O2 yield-
ing a brown precipitate. CRH immunohistochemistrywas performed on
free-floating 50-m vibratome brain sections fixed in 4% paraformal-
dehyde with a rabbit anti-CRH antiserum (1:4000; Peninsula Laborato-
ries, San Carlos, CA) in KPBS buffer, 2% normal goat serum, and 0.3%
Triton X-100 at 4 C for 48 h followed by the steps outlined previously.
In situ hybridization
Initial screening for pHalEx2* transgene expression used a radiola-
beled 23-bp antisense oligonucleotide corresponding to the exon 2 in-
sertion and was performed as described previously (30). Definitive in
situ hybridization studies used single-stranded 700 nucleotide [35S]-
radiolabeled cRNA riboprobes generated by T3/T7 polymerases from a
mouse Pomc template containing exon 3 sequences subcloned into
pGEM-7 (Promega, Madison, WI). The antisense probe hybridized
equally to endogenous and pHalEx2* transgenic PomcmRNA. The Pomc
sense probe was used as a control and produced no specific signal on
pituitary or brain sections. Crh sense and antisense [35S]-radiolabeled
cRNA probes were generated from a 578-bp PstI-PstI fragment con-
tained in exon 2 of the mouse Crh gene (a gift from A. Seasholtz,
University of Michigan) subcloned into pBluescript II (Stratagene, La
Jolla, CA). Probes were separated from unincorporated nucleotides over
NICK columns (Sephadex G-50 DNA Grade; Amersham Pharmacia
Biotech, Piscataway, NJ) and applied to slides containing serial 16-m
coronal sections at 55–60 C for 24 h in hybridization buffer at a con-
centration of 5  106 cpm/ml as described previously (33). After hy-
bridization, slides were washed four times with 150 mm NaCl, 15 mm
Na citrate, pH 7.0 (SSC), digested with RNAseA (30 min), rinsed again
in SSC containing DTT, dehydrated through a series of ethanol concen-
trations, vacuum dried, and analyzed by autoradiography (BiomaxMR;
Kodak, Rochester, NY) followed by phosphoimaging (Molecular Dy-
namics, Eugene, OR). Digital images were analyzed using IP-Lab Gel
andNIH Image. Hybridization signal was quantified in selected regions
of interest with constant area size from each section. Background signal
was quantified from sections not containing any visible specific hybrid-
ization signal and then subtracted from total signal in each section. Pomc
mRNA signal in the ArcN and pituitary was averaged from the three
sections of each tissue with the highest signal per mouse (n  3–4 mice
per genotype).CrhmRNAwas analyzed similarly by averaging the three
most robustly labeled PVH sections per mouse (n  3–6 mice per
genotype).
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Hormone assays
Plasma hormones were measured using a two-site ACTH immuno-
radiometric assay (Nichols Diagnostic Institute, San Juan Capistrano,
CA) and a double antibody corticosterone RIA (MP Biomedicals, Solon,
OH) according to the manufacturers’ instructions. Maximal sensitivity
was achieved by adjusting the plasma dilutions.
Statistics
All data presented are themean se ofmean unless stated otherwise.
Data were analyzed by multifactor analyses of variance appropriate for
the design of each experiment with genotype and sex as independent
variables using StatView version 5.0.1 for Macintosh Power PC (SAS
Institute Inc., Cary, NC). One-factor analyses of variance were used to
follow-up significant main effects and post hoc pairwise comparisons
between groups were performed by the Tukey/Kramer test with a
criterion for significant differences set at P  0.05 unless stated
otherwise.
Results
Transgenic rescue of pituitary POMC in Pomc/ mice
In situ hybridization of tissue sections with a riboprobe
that hybridized to exon 3 sequences common to both the
wild-type Pomc and pHalEx2* Tg alleles, but absent from the
mutantPomc allele, confirmed that the transgene selectively
rescued POMCexpression in intermediate and anterior lobes
of the pituitary but not the ArcN (Fig. 1). The spatial distri-
bution of Pomc mRNA transcribed from the pHalEx2* Tg
allele in the anterior lobes of Pomc/Tg/ mice matched
that of Pomc/ mice and the expression patterns of previ-
ously reported transgene constructions that contained anal-
ogous Pomc promoter regions (29, 30, 34). Quantification of
total pituitaryPomcmRNAhybridization signals revealed no
significant difference between Pomc/Tg/ and Pomc/
mice (Table 1). Furthermore, there was no significant reduc-
tion or increase in Pomc mRNA in Pomc/ vs. Pomc/ or
Tg/ vs. / mice, respectively. Similarly, quantification of
Pomc mRNA in the ArcN revealed no differences among
Pomc/, Pomc/Tg/, Pomc/, and Pomc/Tg/ mice
(Table 1). Immunohistochemistry and RIAs confirmed the
restored production of-endorphin,melanocyte-stimulating
hormone, and ACTH in the pituitary but not hypothalamus
of Pomc/Tg/ mice at physiological levels (28).
Perinatal lethality and adrenal insufficiency characteristic
of Pomc/ mice were reversed in Pomc/Tg/ mice
Breeder pairs of compound Pomc/Tg/ mice produced
the expected Mendelian ratio of genotypes in their offspring
with the exception of Pomc/ mice. Compared with the
60% frequency of perinatal deaths in Pomc/ pups, con-
sistent with previous reports (27, 35), there was no excess
mortality observed in Pomc/Tg/mice. Pomc/ pups that
did not die on postnatal d 1 were indistinguishable by visual
observation from their littermates, regardless of genotype,
until after weaning and they then survived into adulthood
without any specific treatment.
Adult Pomc/ mice of both sexes had small but easily
identifiable adrenal glands by gross inspection of their su-
prarenal fat (Fig. 2A). Microscopic sections revealed a clearly
distinguishable adrenal medulla and cortex, but the cortical
zona fasciculata was decreased in height and the character-
istic columnar cell arrangement was replaced by disorga-
nized, densely packed cells with scant cytoplasm compared
with Pomc/ siblings (Fig. 2B). Pituitary POMC replacement
in Pomc/Tg/ mice resulted in enlarged adrenal glands
primarily due to hypertrophy of the zona fasciculata as in-
dicated by an increased volume of eosinophilic cytoplasm
per cell and decreased numbers of cells per high-power field
(Fig. 2B). A marked sexual dimorphism was apparent in the
Pomc/, Pomc/Tg/, Pomc/, and Pomc/Tg/ geno-
types characterized by nearly a 2-fold greater weight of the
female adrenals (F1,145  170, P  0.0001, main effect of sex)
(Fig. 2C). The atrophic adrenals of male and female Pomc/
mice had similarly low weights, and although pituitary
POMC restoration resulted in adrenal gland enlargement in
both sexes, the percentage increase compared with their re-
spective Pomc/ controls was substantially greater in males
(100%) than females (25%).
Plasma corticosterone was measured previously in un-
stressed 10- to 15-wk-old Pomc/Tg/ and Pomc/Tg/
mice at intervals of 3 h from 0800 to 2000 h (28). Pomc/Tg/
mice exhibited the expected diurnal rhythmof corticosterone
secretion with a nadir early in the light phase and a peak
before the onset of darkness. Female Pomc/Tg/mice had
higher peak corticosterone values than males, paralleling
their sexually dimorphic adrenal size. Although female
Pomc/Tg/mice retained a normal diurnal pattern of cor-
ticosterone secretion with normal basal and only modestly
increased peak values, male Pomc/Tg/ mice exhibited a
strikingly altered pattern of corticosterone secretion with
exaggerated nadir and peak levels. In the current study, basal
morning corticosterone and ACTH levels were measured in
9- to 11-month-old mice of all six genotypes (Table 1). Body
weights of these mice were very similar to our previous
report (28). Pomc/ mice had no detectable level of either
hormone. Excluding this genotype from the analysis of vari-
ance analyses, therewas a significantmain effect of genotype
in male mice for both basal corticosterone (F4,23  9.0, P 
0.0001) andACTH (F4,23 5.7, P 0.005). Pomc
/Tg/mice
had significantly increased basal levels of corticosterone
FIG. 1. Transgenic rescue of pituitary POMC expression in
Pomc/Tg/ mice. Pomc mRNA in situ hybridization was per-
formed on coronal sections of ArcN and pituitary from 6-month-old
male mice of the indicated compound genotypes and representative
autoradiograms are shown. IL, Intermediate lobe; AL, anterior
lobe. Scale bars, 200 m for ArcN and 300 m for pituitary sections.
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compared with all other genotypes. The corresponding in-
crease in ACTH in male Pomc/Tg/ mice was also signif-
icantly different from all other genotypes except Pomc/
mice by the Tukey/Kramer post hoc test; however, a planned
pairwise comparison with Fisher’s projected least significant
difference test gave a P 0.01. Increased basal corticosterone
was further confirmed in neural-specific POMC-deficient
males and also detected in mutant females by analysis of an
independent cohort of 6-month-old mice consisting of lean
Pomc/Tg/Tg and obese Pomc/Tg/Tg genotypes (Table 1).
Notably, homozygosity of the Tg allele on the wild-type
Pomc/ background had no effect on basal corticosterone
levels, body weight, or adrenal weight (adrenal data not
shown).
Altered stress activation of the HPA axis and hypothalamic
CRH expression in Pomc/Tg/ mice
Mice of all genotypes except Pomc/ responded briskly
to an acute 20-min restraint stress with elevated plasma
ACTH (Fig. 3A) and corticosterone (Fig. 3B) relative to their
respective nonstressed levels (Table 1 and Fig. 3, insets).
However, there was a highly significant main effect of ge-
notype for stress-induced ACTH by a two-factor analysis of
variance excluding the Pomc/ group (F4,59  12.6, P 
0.0001). There was also a significant effect of sex (F1,59  6.2,
P  0.05) due to higher ACTH levels in males but no inter-
action between the two factors (F4,59  2.0, P  0.11). The
magnitude of the ACTH stress response was significantly
blunted by 50–75% in both male and female Pomc/Tg/
mice compared with Pomc/ mice or the other responding
groups (Fig. 3A).
Corresponding analyses of the corticosterone response
to restraint stress in the same mice (Fig. 3B) revealed a
highly significant main effect of sex (F1,59  66.9, P 
0.0001) due to higher plasma corticosterone levels in fe-
males. There was also amain effect of genotype (F4,59 2.9,
P  0.05) but no interaction between the two factors (F4,59
 1.6, P  0.19). Other than the absence of detectable
corticosterone after stress in the Pomc/ mice, post hoc
pairwise comparisons among the other groups did not
reach statistical significance for either sex. In a separate
experiment, pair-feeding of Pomc/Tg/ mice to the
daily food intake of Pomc/ mice also resulted in ampli-
fied corticosterone responses in Pomc/Tg/ females
compared with males (data not shown), indicating that the
sexual dimorphism in the response to psychogenic or met-
abolic stressors was maintained in the neural selective
POMC-deficient mice.
Steady-state CRHmRNA levels in the PVHdetermined by
quantitative in situ hybridization were more than 6-fold
higher in Pomc/ mice, which lack all negative glucocor-
ticoid feedback to the central nervous system than Pomc/
mice (F5,13  35.5, P  0.0001; main effect of genotype) (Fig.
4, A and C). Although restoration of pituitary POMC ex-
pression in Pomc/Tg/ mice significantly reduced CRH
mRNA levels relative to Pomc/ mice, these levels still re-
mained 2-fold higher than in the PVH of Pomc/ mice and
inappropriately elevated relative to the increased circulating
corticosterone (Fig. 4C). Pomc/ mice had hypothalamic
CRH mRNA levels that were increased more modestly, but
still significantly, by 50% over that of Pomc/ mice, sug-
gesting a gene dosage effect for neuronal POMC on CRH
levels (F1,11  10.8, P  0.01, data collapsed across pHalEx2*
Tg genotype because there was no main effect of Tg nor a
significant interaction of Tgwith Pomc genotype in an initial
two-factor analysis of variance limited to the four genotypes,
excluding the Pomc/ and Pomc/Tg/ groups). In con-
trast to the expression pattern in the PVH, CRH mRNA was
suppressed in the central nucleus of the amygdala (CeA) of
Pomc/ mice and restored to normal levels in the Pomc/
Tg/ mice (Fig. 4D). Similar levels of expression were ob-
served in the CeA of all other groups.
Immunohistochemical analysis of CRH expression in the
PVH paralleled the results of CRH mRNA in situ hybridiza-
tion (Fig. 4B). As expected, without colchicine pretreatment
to inhibit axonal transport of peptides, there was almost no
TABLE 1. POMC mRNA levels in the pituitary and ArcN, basal hormone levels, and body weight in unstressed mice
Genotype
POMC mRNA (% of Pomc/) Basal hormone levels (EDTA plasma)
Body weight (g)
Pituitary male ArcN male
Corticosterone (ng/ml) ACTH (pg/ml)
Male Female Male Female Male Female
Pomc/ 100  12 100  3 20  2 43  21 17  7 23  4 42  2 34  1
Pomc/Tg/ 63  9 128  45 12  2 66  32 8  6 23  9 43  3 36  2
Pomc/ 74  11 85  15 12  4 22  11 8  4 14  7 47  1 39  2
Pomc/Tg/ 108  17 91  9 16  7 8  2 18  10 22  7 48  2 45  3
Pomc/ 1 2 ND ND ND ND 58  1 54  5
Pomc/Tg/ 76  6 2 84  21a 36  7 50  9b 37  11 74  4a 71  5a
Pomc/Tg/Tg 6  2 16  3 40  2 30  2
Pomc/Tg/Tg 37  11c 49  11c 73  2d 74  2d
Data in the table are the mean  standard error of mean from mice of the indicated genotypes and sex. Mice in the first cohort consisted
of six different genotypes and were age 9–11months (n 3–4mice per group for mRNA; n 4–8mice per group for hormones and body weight,
except n  3 for male Pomc/mice). Mice in the second cohort were homozygous for the pHalEx2* transgene (Tg/Tg) and age 6 months (n 
8–12 mice per group). POMC mRNA was quantified by in situ hybridization using a Molecular Dynamics phosphoimager and NIH Image as
described in Materials and Methods and normalized to mean values for the Pomc/ genotype set to 100%. ND, Not detectable at maximal
sensitivity for the assays.
a P  0.05 vs. all other genotypes (Tukey/Kramer pairwise post hoc comparisons).
b P  0.05 vs. all other genotypes except Pomc/ (Tukey/Kramer pairwise post hoc comparisons).
c P  0.05 vs. Pomc/Tg/Tg (Student’s t test).
d P  0.0001 vs. Pomc/Tg/Tg (Student’s t test).
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immunoreactive CRH detected in cell bodies of Pomc/
mice, but positive neuronal processes were present. In con-
trast, CRH-immunoreactive soma and processes were abun-
dant and strongly labeled in the PVH of Pomc/ mice.
Although not quantified, there also appeared to be moder-
ately more cell body staining of CRH neurons in both
Pomc/ and Pomc/Tg/ compared with Pomc/mice in
parallel with the levels of CRH mRNA expression.
We next tested whether a selective absence of -endorphin
in mice expressing normal levels of melanocortin peptides
would recapitulate the elevated levels of CRH expression ob-
served in the PVH of Pomc/Tg/ mice that lack all central
POMC peptides. Quantitative mRNA in situ hybridization for
CRH was performed in C57BL/6 congenic -endorphin/
and -endorphin/ male mice, which have previously been
demonstrated to have normal adrenal gland size, plasma
ACTH, and corticosterone levels (32). Steady-state levels of
CRHmRNAwere identical between these two groups of mice
(Fig. 4E).
Pomc/ and Pomc/ mice developed pituitary adenomas
Male and female mice, either heterozygous or homozygous
for the Pomc null allele, exhibited a high incidence of pituitary
glands weighing more than 2 sd above the mean of Pomc/
mice after age 12months (Fig. 5). Expression of the pHalEx2* Tg
did not appear to alter either the latency to pituitary tumori-
genesis or the distribution of tumor weights in compoundmu-
tant Pomc/Tg/ or Pomc/Tg/ mice. In most cases, visual
examination of tumors that weighed 10 mg with a stereo-
dissecting microscope revealed enlargement of the intermedi-
ate lobe. In addition to or in place of intermediate lobe tumors,
pituitaries fromPomc/mice frequently containedoneormore
translucent anterior lobe nodules suggesting the presence of
microscopic anterior lobe tumors even when the pituitary
weights were still within normal limits.
Histological analyses were performed to further charac-
terize the pituitary tumors (Fig. 6). Immunostaining revealed
the presence of normal corticotrophs, thyrotrophs, lac-
totrophs, and somatotrophs in the anterior lobe and mela-
notrophs in the intermediate lobe of Pomc/ mice (Fig. 6A,
top row) and Pomc/Tg/ mice (data not shown). The pitu-
itary of a 12-month-old Pomc/ mouse had no immunopo-
sitive staining for ACTH but contained immunonegative
anterior lobe nodules surrounded by cells staining for TSH,
FIG. 2. Adrenal gland morphology, adrenal cortical organization, and
adrenal weights in mutant mice. A, Five-micrometer sections of
6-month-oldmale adrenals stainedwith hematoxylin and eosin showing
relative sizes of hemisected glands. ZF, Zona fasciculata. Scale bar, 400
m.B,Highermagnification of the adrenal cortex showing the histology
of the zona fasciculata. Scale bar, 100 m. C, Wet weights of paired
adrenal glands obtained frommale and femalemice of all six genotypes,
age 10  0.2 months (range, 4–17 months) and excluding mice with
pituitary tumors. Genotypes were equivalently distributed across the
age range and there was not a significant correlation of adrenal weight
with age (r2 0.014; F1,155 2.2,P 0.14). Therewere significantmain
effects of genotype for males (F5,86  53.8, P  0.0001) and females
(F5,60  69.1, P  0.0001). *, P  0.05 compared with all other groups;
and #, P  0.05 compared with Pomc/and Pomc/ groups (Tukey/
Kramer pairwise post hoc analyses).
FIG. 3. Activation of the HPA axis after 20 min of acute restraint
stress. Plasma ACTH (A) and corticosterone (B) levels after stress
compared with levels in basal conditions (insets). Stress data were
obtained frommale and female mice of all six genotypes, age 11 0.5
months (range, 4–20 months) and excluding mice with pituitary tu-
mors. Genotypes were equivalently distributed across the age range
and there was not a significant correlation of ACTH levels with age
(r2  0.049; F1,66  3.4, P  0.07). Neither hormone was detectable
in Pomc/ mice (ND) and therefore these groups were not included
in the analyses of variance. Despite a significant blunting of ACTH
responses in both male and female Pomc/Tg/ mice (*, P  0.05
compared with all other genotypes of the same sex, Tukey/Kramer
post hoc pairwise comparisons), there was not a corresponding at-
tenuation in corticosterone levels.
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PRL, and GH (Fig. 6A, middle row) and FSH (not shown). A
similar pattern of immunostaining was observed in another
10-month-oldPomc/mousewhose pituitary glandwas still
within the normal weight range (data not shown). In con-
trast, ACTH immunostaining of pituitary glands from
Pomc/ mice often revealed tumors that clearly originated
in the intermediate lobe such as the example shown (Fig. 6A,
bottom row). The anterior lobe of this Pomc/ mouse had a
normal distribution of corticotrophs and other cell types.
We observed POMC-positive tumors of widely varying
size that appeared to arise exclusively from the intermediate
lobe not only in Pomc/mice, but also in Pomc/Tg/ and
Pomc/Tg/ mice. Figure 6B shows sections of two repre-
sentative abnormal pituitaries weighing 4.2 mg (top row, left
panel) and 31 mg (all other panels) from Pomc/Tg/ mice.
Both glands contained normal anterior lobe tissue with a
mixture of typical acidophilic and basophilic cell types. Im-
munostaining for GH and PRL was positive only in cells of
the anterior lobe, whereas immunostaining for ACTH re-
vealed scattered corticotrophs in the anterior lobes and con-
tinuous sheets of melanotrophs in the intermediate lobe tu-
mor (Fig. 6B, lower row). Large intermediate lobe tumors
displaced and compressed underlying anterior lobe tissue
and overlying hypothalamus but did not appear to invade
the contiguous structures.
Pituitary tumors originating in both the intermediate and
anterior lobes were observed in Pomc/ mice. Figure 6C
shows two such representative pituitary tumors weighing
8.2 mg and 11 mg. The first pituitary contained a nodular
intermediate lobe composed only of basophilic cells (Fig. 6C,
upper row). Multiple mitotic figures were present per high-
power field. A Gordon-Sweet silver stain revealed areas of
enlarged acini and disrupted reticulin fibers consistent with
hyperplasia, contiguous with frankly adenomatous tissue
characterized by a total loss of all extracellular reticulin ma-
trix. The second pituitary (Fig. 6C, lower row) was composed
of apparently normal intermediate lobe tissue overlying an
enlarged anterior lobe, which contained only a thin margin
of mixed acidophilic and basophilic cells. These marginal
cells were immunopositive for GH and PRL and were ad-
jacent to the large immunonegative mass of tumor cells. The
tumor had the histopathological features of an adenoma,
including loss of the reticulin network, enlarged pleomor-
phic nuclei with numerous mitotic figures, peliosis, and he-
matoid depositions.
To further confirm the presumptive melanotroph and cor-
ticotroph cell type of origin in the nonfunctioning pituitary
tumors of Pomc/ mice, we crossed the Pomc/ genotype
to transgenic mice expressing EGFP, specifically in POMC
cells under control of Pomc gene regulatory elements (31). A
relatively normal-sized pituitary gland from one of these
compound mutant mice showed a medial anterior lobe nod-
ule composed mostly of EGFP-positive corticotrophs as well
as individual EGFP-positive corticotroph cells in the lateral
wings of the anterior lobe and a distinct intermediate lobe of
normal size composed of EGFP-positive melanotrophs (Fig.
6D). A macroadenoma that was several times larger than a
normal pituitary gland was harvested from a second com-
pound mutant Pomc/PomcEGFP-Tg mouse. This tumor
had no grossly identifiable intermediate or anterior lobe
structures but was composed of serpentine cords and sheets
of predominantly EGFP-positive cells surrounding cystic
spaces (Fig. 6E).
Discussion
In the present study, the goal was to establish a model
system to formally test the hypothesis that loss of central
nervous system and pituitary-derived POMC peptides con-
tribute uniquely to the adrenal insufficiency associated with
FIG. 4. CRH expression in the hypothalamus and amygdala of male mice. CRH mRNA was analyzed by in situ hybridization (A) and CRH
peptide by immunocytochemistry (B) on coronal brain sections of 9-month-old Pomc mutant mice. PVH, Paraventricular nucleus of the
hypothalamus; 3V, third ventricle. Scale bars, 1 mm (A) and 200 m (B). C, CRH mRNA levels in PVH were quantified using a phosphoimager
and the data expressed relative to a normalized value of 1.0 forPomc/ controls. (*,P 0.05 compared with all other genotypes, Tukey/Kramer
post hoc pairwise comparisons.) D, CRH mRNA levels in the central nucleus of the amygdala (CeA) were quantified from the same sections
as those containing the PVH and the data expressed relative to a normalized value of 1.0 for Pomc/ controls (F5,13  2.5, P  0.09). E, CRH
mRNA levels in PVH were quantified from congenic C57BL/6 male -endorphin/ and -endorphin/ mice and the data expressed relative
to a normalized value of 1.0 for -endorphin/ controls (F1,9  0.11, P  0.75).
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null mutations of the Pomc gene. Two general strategies have
beenused to differentiate and attribute specific consequences
of gene-inactivating mutations to the spatial location of gene
expression in distinct cell types, tissues, or organs. The first
strategy depends on spatially restricted gene inactivation,
most commonly involving some form of conditional, somatic
cell-based intrachromosomal recombination event (36). A
major difficulty that can limit the use of this approach is the
achievement of complete gene inactivation in the specific
location of interest. In the current studies, we used the al-
ternative genetic approach to create a de facto central nervous
system-specific inactivation of POMC function by the trans-
genic rescue ofPomc gene expression to pituitary cells inmice
with a preexisting targeted null mutation of Pomc affecting
all sites of expression. Previous studies from our laboratory
have identified regulatory elements in the proximal mouse
Pomc promoter that confer high-fidelity in vivo transgene
expression specifically to pituitary corticotrophs and mela-
notrophs with no detectable expression in either the ArcN or
nucleus tractus solitarius (30, 37). In addition to their spatial
selectivity, these promoter elements have also faithfully re-
capitulated the developmental onset, diurnal rhythm, and
stimulatory/inhibitory regulation of Pomc expression by ad-
renalectomy, dexamethasone, metyrapone blockade of glu-
cocorticoid biosynthesis, hypertonic saline, and dopaminer-
gic agonist/antagonist treatment in the anterior and
intermediate pituitary lobes (29, 34, 38).
Rescue of adrenal function
POMC peptides are known to play a critical role in the
development,maturation, and function of the adrenal glands
(25, 39, 40). Our data confirm that the pituitary is a sufficient
source of POMC and that neuronal POMC expression is not
necessary for synthesis and secretion of corticosterone from
the adrenal cortex. In addition to ACTH, which stimulates
adrenal cortical cells by activation of melanocortin-2 recep-
tors, a peptide derived from the aminoterminal half of POMC
by extracellular endoproteolytic cleavage has been reported
to be mitogenic for adrenal cortical cells in vitro (40, 41). The
pHalEx2* transgene encodes all POMC peptides and there-
fore cannot differentiate between the possible contributions
of ACTH and the aminoterminal peptide to the observed
restoration of both adrenal gland morphology and function;
however, two recent studies by Coll et al. (25, 42) involving
the injection of an ACTH analog (1–24 ACTH, synacthen) or
the short peptide derived from the aminoterminal region of
POMC (1–28 POMC) to Pomc/ mice strongly suggest that
FIG. 5. Distribution of pituitary
weights in male and female compound
Pomc mutant mice. The scatterplots
show the wet weights of pituitary
glands (logarithmic y-axis) obtained
from 4- to 26-month-old mice of the in-
dicated genotypes.Dotted lines indicate
2 SD values above the mean weights of
male or female pituitary glands from
Pomc/mice.Most of themice showed
no obvious signs of pituitary disease
and were killed for other purposes or at
the indicated ages to obtain a snapshot
of tumor development over time. Mice
with tumor weights greater than 50 mg
were more likely to have developed a
head tilt, bulging cranium, arched back,
or rapid weight loss and were killed
when those signs were apparent.
Smart et al. • Neuronal POMC Modulation of the HPA Axis Endocrinology, February 2007, 148(2):647–659 653
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 09 April 2015. at 09:54 For personal use only. No other uses without permission. . All rights reserved.
ACTH is the critical product secreted by pituitary cortico-
trophs. This latter conclusion is further supported by our
observation that another pituitary-specific transgene pHal*
that encodes the amino-terminal POMC peptide and -en-
dorphin, but not ACTH (10), failed to restore corticosterone
production after intercrossing with Pomc/ mutant mice
(Smart, J.L., and M.J. Low, unpublished data).
Activation of the HPA axis
Expression of the pHalEx2* transgene on the WT genetic
background (Pomc/Tg/) did not result in increased levels
of pituitary POMC mRNA and peptides or alterations in
either basal or stress-induced plasma ACTH and corticoste-
rone. These findings are consistent with our previous studies
of analogous pituitary-specific POMC transgenes (29) and
suggest that introduction of the extra Pomc Tg allele is bal-
anced by a coordinated regulation of WT and Tg allele ex-
pression to maintain normal HPA activity with no net gain
of function. Similarly, the loss of one functional Pomc allele
in the heterozygous Pomc/ mice did not result in a signif-
icant decrease in pituitary POMCmRNA levels or decreased
basal activity of the HPA axis. Evidently, expression of the
remaining normal allele was up-regulated to restore ho-
meostasis at the level of the pituitary. The same was not true
for hypothalamic expression of POMC, in which a 50% re-
duction in  melanocyte-stimulating hormone content was
FIG. 6. Histological analysis of pituitary tumors in
Pomc mutant mice. A, Immunohistochemical local-
ization of ACTH, TSH, PRL, and GH in coronal pitu-
itary sections from 11- to 12-month-old male mice.
Arrows indicate a normal intermediate lobe (IL) (top
row) and a melanotroph IL tumor (bottom row) in
Pomc/ and Pomc/ mice, respectively. Arrow-
heads indicate a large anterior lobe (AL) nodule that
does not express any pituitary hormone in a Pomc/
mouse (middle row). NL, Neural lobe. Scale bar, 300
m. B, Early (top left) and late-stage (top middle) IL
tumors (*) from 11- and 15-month-old female
Pomc/ Tg/ mice, respectively. The remaining
panels are higher-magnification photomicrographs of
the area indicated by the square. Hematoxylin and
eosin staining (top right) shows the boundary between
normalAL,which contains numerous pink acidophilic
cells (arrows), and adenomatous IL. Melanotrophs in
the IL tumor are uniformly positive for ACTH immu-
noreactivity but negative for GH and PRL (bottom
row). Scale bars represent either 120 m (first two
panels) or 30 m. C, (Top row) IL pituitary tumor in
a 10-month-old female Pomc/ mouse. Tumor nod-
ules (*) are adjacent to areas of relatively normal
melanotrophs and a colloidal cyst (cc). Numerous mi-
totic figures are present (arrows). Gordon-Sweet sil-
ver stain reveals areas of hyperplasia with enlarged
acini (arrowheads) adjacent to frank adenoma (*) (top
right).Bottom row, AL pituitary tumor in a 15-month-
old male Pomc/ mouse. Hematoxylin and eosin
staining reveals residual normal AL containing pink
acidophils (arrows) adjacent to basophilic adenoma.
GH and PRL immunoreactive cells are only present in
the normal AL tissue. Reticulin fibers are condensed
at the border between normal AL and adenoma (ar-
rowhead) and disrupted or completely absent in the
adenoma (*). Scale bars, 300 m (panel I), 120 m
(panel II), 20 m (panel III), and 30 m (panel IV and
bottom row). D, EGFP-positive, presumptive cortico-
troph tumor (*) in the AL of a compound mutant
Pomc/PomcEGFP-Tgmouse. Scale bar, 300 m. E,
Portion of a large pituitary tumor with no grossly
identifiable structure from an 18-month-old Pomc/
PomcEGFP-Tg mouse. Tumor cells are variably pos-
itive for EGFP fluorescence and surround numerous
cyst-like cavities (*). Scale bar, 120 m.
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previously shown (28). Although we observed a statistically
nonsignificant trend for reduced levels of POMC mRNA in
theArcN ofPomc/ comparedwithPomc/mice, the quan-
titation of expression by in situ hybridization may have been
insufficiently sensitive to detect a biologically meaningful
reduction. There were clear phenotypic effects of the het-
erozygous genotype on both body weight (28) and hypo-
thalamic CRH expression (discussed subsequently) indicat-
ing that a reduction in neuronal levels of POMCpeptideswas
disproportionately greater than changes in steady-state lev-
els of POMC mRNA in the Pomc/ mice.
Despite the absence of any detectable gain-of-function
phenotype attributable to pHalEx2* expression in the WT
genetic background, transgenic restoration of pituitary Pomc
expression in Pomc/mice induced excessive activity of the
HPA axis. The phenotype was evident in both sexes but was
substantially more severe in males and characterized by in-
creased adrenal cortical mass and elevated basal diurnal
levels of corticosterone and plasma ACTH. Other studies
have similarly demonstrated the existence of a sexual di-
morphism in the HPA activity in rodents (43) dependent on
the estrous cycle and likely attributed to the actions of es-
tradiol. Because ovarian steroid effects are partly mediated
through the hypothalamus and in particular estrogens mod-
ulate ArcN POMC neurons (44), lack of central POMC in
Pomc/Tg/ mice can partly explain the differences in the
HPA axis responsiveness between males and females.
Based on microscopic observation, hypertrophy of indi-
vidual zona fasciculata cells appeared to be the primary
cause of the increased adrenal mass consistent with previous
studies on the effects of chronic ACTH stimulation on rodent
adrenals (45–47) and the administration of a potent, long-
acting ACTH analog to adult Pomc/ mice (25, 42). Mark-
edly enlarged adrenal glands due to hypertrophy of the
adrenal zona fasciculata with concomitant hypercorticoste-
ronemia have also been described secondary to elevated
plasma ACTH levels in a rat model overexpressing CRH
from transplanted medullary thyroid carcinoma cells (48).
Despite blunted ACTH responses after restraint stress, both
male and female Pomc/Tg/mice responded with normal
or slightly increased plasma corticosterone levels, suggesting
increased adrenal sensitivity to ACTH stimulation. The rea-
sons for this accentuated response in the Pomc/Tg/mice
is unclear but could be mediated through an up-regulation
of the adrenal ACTH receptor.
The phenotype of excessive basal HPA activation, together
with the observed significant attenuation in stress-induced
ACTH secretion in both sexes, also suggested a central ner-
vous system defect in the regulation of the HPA axis in
Pomc/Tg/ mice. We therefore examined expression of
CRH, the principal secretagogue of ACTH, in the PVH and
found that CRH mRNA was inappropriately elevated rela-
tive to the hypercorticosteronemia in these mice. Presum-
ably, the increased Crh gene expression was accompanied by
increased synthesis and secretion of CRH causing the ele-
vated basal ACTH. Previous studies examining the correla-
tion of pituitary POMCmRNA levels and circulating ACTH
in Crh KO mice have shown discrepancies between the two
measures, which suggest independent actions of CRH re-
ceptor stimulation and glucocorticoid receptor inhibition on
Pomc gene expression and ACTH secretion (49, 50). Indeed,
a direct inhibitory feedback to Pomc transcription in pituitary
corticotrophs by the elevated corticosterone in Pomc/Tg/
mice would explain the paradoxically normal levels of basal
pituitary POMC mRNA accompanied by increased plasma
ACTH. The attenuated increase in ACTH secretion in re-
sponse to an acute stress is likely due to a combination of
receptor desensitization to chronic CRH stimulation, a rel-
ative depletion of releasable pools of ACTH secretory gran-
ules, and/or feedback inhibition at the pituitary level by the
higher than normal circulating corticosterone.
The classical viewpoint of negative feedback regulation of
glucocorticoids on PVH CRH expression is sufficient to ex-
plain themarkedly increased levels of CRHmRNAobserved
in the hypothalamus of Pomc/ mice by a mechanism of
disinhibition (3, 51). However, the fact that we also observed
high levels of CRH mRNA in the face of elevated cortico-
sterone suggests that the hormone’s ability to inhibit Crh
expression in the PVH has been disrupted and/or circum-
vented in Pomc/Tg/ mice. Perhaps equally remarkable,
heterozygous Pomc/ mice (with or without pHalEx2*
transgene expression) also had significantly increased CRH
mRNA providing additional evidence for an altered homeo-
static set point in regulation of the limbic-HPA axis. Recent
evidence from the Dallman laboratory and others indicates
that corticosterone actually has dual feedback effects in the
central nervous system that are dependent on physiological
state including energy balance (22, 23). Under normal con-
ditions, corticosterone exhibits an inhibitory action to main-
tain basal activity of the HPA axis, whereas under chronic
stress conditions, corticosterone has a facilitatory effect on
HPA activity. Adrenalectomy has been shown to result in a
decrease in hypothalamic melanocyte-stimulating hormone
content, whereas dexamethasone restores these levels in rats
(21), suggesting that hypothalamic POMC peptides may be
required for the full suppressive effect of glucocorticoids on
PVH CRH expression. In a recent study that used a different
strain of global POMC-deficient mice than in our work,
chronic administration of corticosterone in the drinking wa-
terwas apparently sufficient to restoreCRHexpression to the
levels found in wild-type animals (52). However, differences
in the plasma corticosterone levels and pattern between the
Pomc/Tg/ mice and Pomc/ mice supplemented with
glucocorticoids in drinking water, timing for the analysis of
CRH expression as well as genetic backgrounds may explain
these discrepancies.
Our data demonstrating increased CRH expression in the
PVH of mice with a central nervous system specific defi-
ciency of POMC, regardless of whether corticosterone levels
were low, normal, or high, implies that POMC neurons are
a physiologically important component of the neural circuits
regulating the limbic-HPA axis. This role of POMC neurons
appears to be specific to control of CRH in the PVH, because
CRH expression in the central nucleus of the amygdala was
suppressed in Pomc/ mice and up-regulated normally by
restoration of circulating corticosterone. There is a direct
synaptic projection of POMCneurons from the ArcN to CRH
neurons in the PVH, melanocortin-4 receptors have been
colocalized to CRH neurons, and melanocortins have func-
tional effects on CRH neurons (14, 15, 17). Our observations
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support a net inhibitory effect of POMConCRHneurons, but
we cannot distinguish at this point whether the loss of 
melanocyte-stimulating hormone, possibly in combination
with the loss of -endorphin or any of the other POMC-
derived peptides is responsible for this. A few studies have
described opposite effects of melanocortin agonists on CRH
expression or release. In themouse, central administration of
melanocortin agonists activatedCRHneurons throughmela-
nocortin-4 receptors (14). However, stimulatory effects of
AgRP, a melanocortin receptor antagonist, on ACTH and
cortisol have been reported and are more consistent with an
inhibitory effect of endogenous  melanocyte-stimulating
hormone on the HPA axis (53). In ex vivo models,  mela-
nocyte-stimulating hormone was shown to either stimulate
or suppress CRH release from rat hypothalamic explants (15,
54, 55). Similarly, pharmacological studies of  receptor ago-
nists administered centrally or applied in vitro to hypotha-
lamic preparations have also had mixed effects on CRH
secretion depending on dose and other experimental vari-
ables (56–58). In addition, the observed lack of effect on CRH
mRNA levels in -endorphin-deficient mice speaks against
a critical inhibitory role of the POMC opioid peptides. The
reasons for these discrepancies are unclear but may be ex-
plained by the differences between acute pharmacological
treatments and chronic absence of the endogenous peptides.
It remains possible that there is an indirect or more com-
plex integration of opposing effects from melanocortins and
-endorphin on CRH neurons. One possibility is that the
absence or reduction in central POMC might indirectly alter
the set point for CRH neuron activity relative to circulating
corticosterone levels by a polysynaptic pathway. For exam-
ple, immunohistochemical analysis has revealed  melano-
cyte-stimulating hormone and -endorphin immunoreactiv-
ity in the dorsal raphe, a predominantly serotonergic nucleus
that is also innervated by CRH projections (8, 59, 60). Fur-
thermore, dorsal raphe serotoninergic neurons reciprocally
innervate neuroendocrine control regions in both the PVH
(61) and ArcN (62) and activation of 5-HT2A serotonin re-
ceptors on CRH neurons stimulates CRH release and in-
creased plasma ACTH levels (63). Inhibition of these sero-
toninergic neurons by POMC peptides could decrease the
serotonergic stimulation of CRH in the PVH, providing an
indirect regulation of CRH by POMC neurons via the dorsal
raphe nucleus. Additional experiments are needed to further
clarify the actual mechanisms responsible for increased CRH
tone in the neuronal-specific POMC-deficient mice.
Pituitary tumor induction
Although there was hormonal evidence for abnormal ac-
tivation of the HPA axis in 3-month-old male Pomc/Tg/
mice based on their elevated corticosterone levels, no gross
morphological abnormalities of the pituitary gland were ap-
parent in any genotype until age 10 mo. After that point, we
observed an age-dependent, increased incidence of pituitary
tumors that appeared to plateau at approximately age 15
months in male and female mice with either a partial
(Pomc/) or complete (Pomc/) loss of POMC. Restoration
of pituitary POMC expression had no apparent effect on the
incidence of tumor development, implicating a loss of neu-
ronal POMC specifically in the pathogenesis of this pheno-
type. Most of the tumors observed, whether derived from
melanotrophs or corticotrophs, were adenomas based on the
disruption or loss of the reticulin network and high mitotic
index. A common feature of all fourmutant genotypes show-
ing adenoma development was their variable increase in
hypothalamic CRH expression. Based on our observations
and previous data in mice suggesting that hypothalamic
factors can profoundly influence pituitary tumor develop-
ment and progression from other cell types, we hypothesize
that chronic exposure of pituitary corticotrophs and mela-
notrophs to the hypothalamic hormoneCRHaccounts for the
stochastic development of these tumors.
The trophic potential of hypothalamic hormones including
GHRHandCRHhas been documented previously.Mice that
overexpress human GHRH under the control of the metal-
lothionein promoter develop pituitary tumors with hyper-
plasia (64) and subsequently frank adenomas (65). In hu-
mans, GHRH-producing tumors can cause acromegaly
associated with somatotroph proliferation and hyperplasia
(66, 67). Similarly, patients with long-term exposure to CRH
excess from ectopic CRH-producing tumors develop Cush-
ing’s syndrome, which has been associated in some cases
with corticotroph hyperplasia (45, 68) and adenoma (69).
In the Pomc mutant mice, adenomas were associated in
most cases with some evidence of hyperplasia that could be
a consequence of elevated CRH levels. Indeed, chronic ad-
ministration of CRH has been associated with an increase in
corticotroph and melanotroph cell number (46, 70) due to
increased mitogenic activity (71). If chronically increased
CRH is sufficient to produce the observed trophic stimula-
tion of the pituitary gland, we would expect that other CRH
overexpressing mice would also develop tumors. Two
strains of transgenic mice with central overexpression of
CRH from different promoters have been independently
generated by different laboratories (72, 73). Interestingly,
both show an activated HPA axis, but neither strain has been
reported to develop pituitary tumors. However, the first
strain has a shortened lifespan such that mice rarely reach an
age of 10 mo, the minimum age when adenomas were evi-
dent in our studies. It is unclear if the second strain has been
specifically evaluated for abnormal pituitary histology.
Two distinct types of adenomaswere observed depending
on genotype of the mice. Both corticotroph andmelanotroph
tumors were present in Pomc/ mice, whereas only mela-
notroph tumors developed in the other three mutant geno-
types. This difference in tumor cell origin could be secondary
to a dose-dependent stimulatory effect of CRH. Pomc/
mice exhibited the highest hypothalamic CRH expression (a
6-fold increase relative to control siblings compared with a
more modest 1.5- to 2-fold increase in the other genotypes).
A second, but not mutually exclusive, hypothesis relates to
the inhibitory feedback actions of glucocorticoids on pitu-
itary corticotrophs but not on melanotrophs because of their
cell-specific pattern of glucocorticoid receptor expression (6).
Such feedback is completely absent in Pomc/ mice with
undetectable plasma corticosterone. Changes in glucocorti-
coid status have been associated with altered pituitary mi-
totic and apoptotic activities in animal models. Adrenalec-
tomy in the rat is accompanied by increased mitotic activity
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for about 7 d, whereas the frequency of apoptosis is un-
changed, resulting in a net increase of trophically sensitive
cells. In contrast, glucocorticoid replacement in adrenalec-
tomized animals is associated with a low mitotic index and
high occurrence of apoptosis, resulting in a drop in total
pituitary cell proliferation (74). Those data suggest that cells
undergoing mitosis are sensitive to apoptotic activity in the
presence of glucocorticoids, thus protecting against cell pro-
liferation and hyperplasia. In contrast, corticosterone with-
drawal induces mitosis without equivalent apoptosis, thus
favoring cell division and hyperplasia. As a consequence,
normal or elevated levels of corticosterone may prevent tu-
mors of corticotrophs via the established negative effect on
corticotroph proliferation (75) in Pomc/Tg/, Pomc/, and
Pomc/Tg/ mice. However, melanotrophs that lack func-
tional glucocorticoid receptors could respond continuously to
the chronic CRH stimulatory signal.
Lack of production of melanocyte-stimulating hormone
in POMC-deficient mice could also contribute to the devel-
opment of intermediate lobe tumors. Indeed, a recent set of
studies demonstrate that re-expression of the retinoblastoma
gene (Rb) selectively in melanotroph cells in Rb/ mice
protects against melanotroph adenomas but accelerates the
progression of noncorticotroph anterior lobe adenomas.
Overproduction of melanocyte-stimulating hormone in the
melanotroph cells suggests a paracrine role of melanocortin
peptides in regulating cell growth and apoptosis (76) and
supports the hypothesis of a protective action of  melano-
cyte-stimulating hormone against the progression of mela-
notroph tumors.
Finally, we cannot exclude that other factors such as a
potential lack of dopamine tone in POMC-deficient mice
induce or modulate the development of pituitary tumors.
However, this seems to be an unlikely primary mechanism
because dopamine D2 receptor-deficient mice, which have a
complete lack of dopamine tone at the intermediate lobe of
the pituitary, never developed melanotroph tumors (Low,
M.J., unpublished data; and Ref. 77).
In conclusion, our data show that central nervous sys-
tem and pituitary-derived POMChave unique functions in
regulating the HPA axis. Furthermore, pituitary-derived
POMC does not compensate for the loss of central nervous
system POMC. Although there is evidence for limited
transport of POMC peptides across the blood-brain barrier
(78), conventional wisdom holds that central nervous sys-
tem and pituitary-derived POMC constitute separate com-
partments with distinct biological roles, and the current
data further indicate specific roles for POMC peptides in
the central nervous system vs. pituitary. Additionally,
these data show that POMC has dual regulatory roles at
multiple levels of the HPA axis, most interestingly regu-
lating CRH expression in the PVH in addition to glucocor-
ticoid secretion from the adrenals.
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